<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39418956</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-035X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of infection and public health</Title><ISOAbbreviation>J Infect Public Health</ISOAbbreviation></Journal><ArticleTitle>Sex, vaccination status, and comorbidities influence long COVID persistence.</ArticleTitle><Pagination><StartPage>102562</StartPage><MedlinePgn>102562</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jiph.2024.102562</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-0341(24)00296-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is interest in the public health impact of Long COVID, defined as symptoms that persist or begin after SARS-CoV-2 infection. We aimed to identify demographic and clinical risk factors associated with Long COVID over time in an Upper Middle-Income Country (UMIC) and potential biomarkers predictive of symptom trajectory.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Prospective cohort study of adults with mild SARS-COV-2 during the Omicron period. We tracked symptom persistence and IgG antibody titers against the spike S1 subunit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 383 participants, 276 had confirmed SARS-CoV-2 infection. Long COVID persisted for &#x2265;&#xa0;two months in 21&#xa0;% and &#x2265;&#xa0;12 months in 5&#xa0;%. The most common symptoms were fatigue, upper respiratory symptoms, and myalgia/arthralgia: 15&#xa0;% had fatigue for &#x2265;&#xa0;one month, 10&#xa0;% for &#x2265;&#xa0;two months, and 5&#xa0;% &#x2265;&#xa0;three months. Upper respiratory symptoms lasted &#x2265;&#xa0;one month in 17&#xa0;%, &#x2265;&#xa0;two months in 7&#xa0;%, and &#x2265;&#xa0;three months in 3&#xa0;%. Fully 9&#xa0;% reported myalgia/arthralgia lasting &#x2265;&#xa0;one month, 6&#xa0;% &#x2265;&#xa0;two months, and 4&#xa0;% &#x2265;&#xa0;three months. Risk factors for symptom persistence included female sex, not being fully vaccinated, and comorbidities. Participants experiencing persistent fatigue had lower anti-S1 IgG titers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this population, symptom persistence declined after the acute phase, but 5&#xa0;% of participants did not fully recover. Even in a population that was almost fully vaccinated, women, individuals with comorbidities, and the few remaining people who were unvaccinated were at greater risk for Long COVID. Immunoglobulins may have utility as a biomarker of Long COVID fatigue in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fuller</LastName><ForeName>Trevon</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores Mamani</LastName><ForeName>Roxana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Graduate Program in Tropical Medicine, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;RJ&#xa0;Cep: 21.040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira Pinto Santos</LastName><ForeName>Helo&#xed;sa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Graduate Program in Public Health, S&#xe9;rgio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rua Leopoldo Bulh&#xf5;es 1.480, Manguinhos, Rio de Janeiro,&#xa0;RJ&#xa0;Cep: 21.041-210, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melo Esp&#xed;ndola</LastName><ForeName>Ot&#xe1;vio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guaraldo</LastName><ForeName>Lusiele</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes Melo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borges Da Silva</LastName><ForeName>Michele Fernanda</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Graduate Program in Tropical Medicine, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;RJ&#xa0;Cep: 21.040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral Calvet</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares Bastos</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Scientific Computation Program, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;RJ Cep: 21.040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Mar&#xed;lia S&#xe1;</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Scientific Computation Program, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;RJ Cep: 21.040-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brasil</LastName><ForeName>Patr&#xed;cia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Acute Febrile Illnesses Laboratory, Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos,&#xa0;Rio de Janeiro,&#xa0;Cep: 21.040-360&#xa0;RJ, Brazil. Electronic address: patricia.brasil@ini.fiocruz.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect Public Health</MedlineTA><NlmUniqueID>101487384</NlmUniqueID><ISSNLinking>1876-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort Studies</Keyword><Keyword MajorTopicYN="N">Immunoglobulin G</Keyword><Keyword MajorTopicYN="N">Post-Acute COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">Risk Factors</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39418956</ArticleId><ArticleId IdType="doi">10.1016/j.jiph.2024.102562</ArticleId><ArticleId IdType="pii">S1876-0341(24)00296-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>